ModifiedUnitedHealthcarePolicy CS166NE.O

Lower Extremity Endovascular Procedures (for Nebraska Only)

UnitedHealthcare medical policy governing endovascular revascularization procedures for lower extremity peripheral artery disease in Nebraska; defines coverage criteria, exclusions, required documentation, and applicable codes for providers and reviewers.

Policy Summary

PayerUnitedHealthcare

PolicyLower Extremity Endovascular Procedures (for Nebraska Only)

Policy CodePolicy CS166NE.O

Change TypeRevised coverage criteriaadded in‑stent restenosis retreatment criteriaclarified imaging and documentation

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization with medical records and imaging showing symptoms, impaired ADLs/work, and target‑vessel stenosis ≥50% (use alternative imaging if duplex does not show ≥50%).

SourceLink

POLICY UPDATE CHANGES

Revised medically necessary coverage criteria for endovascular revascularization procedures for treating non-limb-threatening lower extremity ischemia in individuals with claudication of the aortoiliac and/or femoropopliteal arteries.

Added criteria that retreatment for in-stent restenosis is proven and medically necessary when recurrent symptoms, impaired ADLs/work, and imaging demonstrating ≥50% stenosis are present.

Added language clarifying medical records documentation may be required to assess whether the member meets clinical criteria and that documentation must fully support medical necessity.

Clarified acceptable imaging modalities (duplex, CTA, MRA, digital subtraction angiography) and updated imaging requirement language.

Updated Supporting Information, Clinical Evidence and References sections to reflect current information.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Endovascular Revascularization

Non-limb-threatening Claudication — Initial endovascular revascularization

Covered when ALL of the following are met for non‑limb‑threatening claudication due to aortoiliac and/or femoropopliteal atherosclerotic disease:

Functional impairment: Impaired ability to work and/or perform activities of daily living (ADL)

Conservative therapy: All of the following: at least 12 weeks of Supervised Exercise Therapy or a Structured Community-Based Exercise Program; pharmacologic therapy (e.g., lipid‑lowering, antihypertensive, antiplatelet, and/or anticoagulant therapy); and smoking cessation, if applicable.12 weeks

Hemodynamic evidence: Ischemic peripheral artery disease with Ankle‑Brachial Index (ABI) ≤ 0.90.ABI <= 0.90

Anatomic imaging: Imaging of the target vessel (e.g., duplex ultrasound, CTA, MRA, or digital subtraction angiography) demonstrates anatomic location and a moderate–severe stenosis (50% or greater); if duplex ultrasound does not demonstrate ≥50% stenosis, another imaging modality is required to demonstrate extent of stenosis.>=50%

Retreatment for in-stent restenosis

Retreatment for in‑stent restenosis is covered when ALL of the following are met:

Symptoms: Recurrent symptoms attributable to the treated lesion.

Functional impairment: Impaired ability to work and/or perform activities of daily living (ADL).

Imaging confirmation: Imaging of the previously treated vessel (e.g., duplex ultrasound, CTA, MRA, or digital subtraction angiography) shows anatomic location and a moderate–severe stenosis (50% or greater); if duplex ultrasound does not demonstrate ≥50% stenosis, another imaging modality is required to demonstrate extent of stenosis.>=50%

Chronic Limb-Threatening Ischemia

Covered for Chronic Limb‑Threatening Ischemia (CLTI):

Indication: Endovascular revascularization is proven and medically necessary for treating CLTI when the diagnosis corresponds to the Applicable Codes listed for CLTI.

See Applicable Codes section for diagnosis list.

Clinical evidence considerations

Evidence-based considerations when selecting revascularization strategy

Systematic review findings: Pegler et al. (2025) systematic review/meta‑analysis found no significant difference in major amputation or mortality between bypass and endovascular revascularization; bypass was associated with lower reintervention rates.

Supports that both approaches are reasonable; durability differs.

BEST-CLI trial results: BEST-CLI trial (Farber et al.) enrolled CLTI patients into two cohorts by vein conduit suitability: Cohort 1 (suitable single‑segment great saphenous vein) showed lower major adverse limb event or death with surgical bypass; Cohort 2 (no suitable vein) showed similar outcomes between surgical and endovascular approaches.

Conduit suitability influences choice of revascularization.

Endovascular vs conservative therapy for claudication: Cochrane review (Fakhry et al., 2018) found endovascular revascularization and supervised exercise produce comparable improvements in walking distance and quality of life; combination therapy may provide greater gains.

Conservative therapy is a reasonable initial option for intermittent claudication.

Medically necessary: Endovascular revascularization for claudication

Revised medically necessary coverage criteria for endovascular revascularization and for retreatment of in‑stent restenosis

Revascularization for claudication (summary): Endovascular revascularization is medically necessary for non‑limb‑threatening lower extremity ischemia (claudication) of the aortoiliac and/or femoropopliteal arteries when guideline‑directed conservative therapy has failed and imaging of the target vessel demonstrates anatomic location and a moderate–severe stenosis (50% or greater).stenosis >=50%

Full detailed criteria (symptoms, conservative therapy duration, ABI requirement) are in other policy sections.

Medically necessary: Retreatment for in-stent restenosis

Retreatment for in‑stent restenosis is considered proven and medically necessary when ALL of the following are met:

Retreatment for in‑stent restenosis: 1) Recurrent symptoms; 2) Impaired ability to work and/or perform activities of daily living (ADL); 3) Imaging of the previously treated vessel (e.g., duplex, CTA, MRA, or digital subtraction angiography) demonstrates anatomic location and a moderate–severe stenosis (50% or greater); if duplex ultrasound does not demonstrate ≥50% stenosis, another imaging modality is required.stenosis >=50%

These added criteria clarify when retreatment is covered.

Endovascular revascularization — initial and retreatment criteria

Covered when ALL of the following are met:

Imaging-confirmed target lesion: Imaging results of the target vessel (e.g., duplex ultrasound, CTA, MRA, or digital subtraction angiography) show anatomic location and a moderate–severe stenosis (50% or greater).>=50%

If duplex ultrasound does not demonstrate >=50% stenosis, another imaging modality is necessary to demonstrate extent of stenosis

Clinical and functional criteria: Impaired ability to work and/or perform activities of daily living (ADL) and, for claudication, failure of guideline‑directed conservative therapy (including at least 12 weeks of supervised or structured exercise and appropriate pharmacologic therapy).12 weeks

For CLTI, applicable diagnosis codes apply and revascularization is considered proven and medically necessary.

Retreatment (in‑stent restenosis) specific:

The policy excludes several clinical situations in which endovascular procedures are not considered appropriate or are unproven. Specifically, interventions performed for non‑limb‑threatening infrapopliteal artery disease (for example anterior tibial, posterior tibial, or peroneal arteries) and procedures performed in an asymptomatic individual are not intended uses for covered revascularization procedures. The policy also states procedures intended solely to prevent progression of claudication to CLTI are not supported. In addition, transluminal peripheral atherectomy of the iliac artery is listed among interventions considered unproven/not medically necessary, and professional guidance rates iliac atherectomy as rarely appropriate across clinical scenarios due to limited comparative data and safety concerns. Finally, the DETOUR endovenous femoropopliteal bypass approach is recognized as investigational in some contexts and is not established as equivalent to open bypass in high-quality comparative trials.

Clinical decision-making should incorporate guideline-directed conservative management and lesion-specific factors. For intermittent claudication, structured exercise and guideline-directed medical therapy are recommended first-line options; endovascular revascularization is considered when symptoms remain lifestyle‑limiting despite these measures. The evidence base (systematic reviews) indicates endovascular therapy and supervised exercise produce comparable improvements in walking distance and quality of life, and combination therapy may provide additional benefit. Lesion characteristics such as anatomic location, lesion length, and degree of calcification inform the choice between endovascular and surgical approaches.

Atherectomy of the iliac artery is noted to have insufficient quality evidence supporting its safety and efficacy. Available studies are predominantly retrospective, single‑arm, or nonrandomized with small and heterogeneous patient populations, and there is a documented risk of life‑threatening perforation. Given the limited and low‑quality data, iliac artery atherectomy is generally considered rarely appropriate and not supported as standard therapy.

This Medical Policy is provided for informational purposes to assist interpretation of UnitedHealthcare standard benefit plans and does not constitute medical advice. Benefit coverage is determined by applicable federal, state, or contractual requirements; in the event of any conflict, those federal, state, or contractual terms govern. Users should verify plan‑specific benefits and authorization requirements before relying on this policy.

Examples of specific procedures referenced in the coverage discussion include transluminal peripheral atherectomy of the iliac artery (CPT descriptor: transluminal peripheral atherectomy; iliac artery, code 0238T) and endovascular techniques such as angioplasty and stent placement for aortoiliac and femoropopliteal disease. The policy explicitly identifies transluminal peripheral iliac atherectomy as an unproven/not medically necessary procedure for PAD.

When concluding that a treatment is not medically necessary, the policy compares available evidence to conservative therapy options. Systematic reviews find that supervised exercise and endovascular revascularization produce comparable improvements for intermittent claudication; therefore, procedures lacking adequate evidence of superior patient‑centered outcomes (for example some novel or device‑specific techniques) may be judged unproven when they do not demonstrate benefit beyond structured exercise and medical therapy.

Novel percutaneous technologies such as the DETOUR endovenous femoropopliteal bypass system are described as promising but remain supported primarily by single‑arm, nonrandomized studies. The policy emphasizes that available DETOUR data are low to very‑low quality and that larger, high‑quality comparative trials versus established surgical bypass or other standards of care are needed before broad coverage or equivalence can be assumed.

Applicable Codes and Key Clinical Thresholds

Applicable CPT / HCPCS Procedure Codesmixed

0238T	Transluminal peripheral atherectomy; iliac artery, each vessel.
0505T	Endovenous femoral-popliteal arterial revascularization with transcatheter placement of intravascular stent graft(s).
37220	Revascularization, endovascular, iliac artery, unilateral; with transluminal angioplasty.
37221	Revascularization, endovascular, iliac artery, unilateral; with transluminal stent placement(s).
37222	Revascularization, endovascular, each additional ipsilateral iliac vessel; with transluminal angioplasty.
37223	Revascularization, endovascular, each additional ipsilateral iliac vessel; with transluminal stent placement(s).
37224	Revascularization, endovascular, femoral, popliteal artery(s), unilateral; with transluminal angioplasty.
37225	Revascularization, endovascular, femoral, popliteal artery(s), unilateral; with atherectomy.
37226	Revascularization, endovascular, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s).
37227	Revascularization, endovascular, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s) and atherectomy.

1–10 of 18

1/2

Applicable ICD-10 Diagnosis Codes (partial list)ICD-10

E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene.
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene.
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene.
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene.
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene.
I70.221	Atherosclerosis of native arteries of extremities with rest pain, right leg.
I70.222	Atherosclerosis of native arteries of extremities with rest pain, left leg.
I70.223	Atherosclerosis of native arteries of extremities with rest pain, bilateral legs.
I70.228	Atherosclerosis of native arteries of extremities with rest pain, other extremity.
I70.229	Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity.

1–10 of 15

1/2

Applicable ICD-10-CM Diagnosis CodesICD-10

I70.421	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, right leg
I70.422	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, left leg
I70.423	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, bilateral legs
I70.428	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, other extremity
I70.429	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, unspecified extremity
I70.431	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of thigh
I70.432	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of calf
I70.433	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of ankle
I70.434	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of heel and midfoot.
I70.435	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of foot.

1–10 of 233

1/24

Supervised Exercise Therapy duration — at least 12 weeks.

Required durationSupervised Exercise Therapy or Structured Community-Based Exercise Program for at least 12 weeks (minimum)

Session lengthSupervised sessions: training performed for a minimum of 30–45 minutes per 60-minute session

Session frequencyPerformed at least 3 times per week

Program settingSupervised therapy takes place in a hospital or outpatient facility; structured community programs occur in the patient’s personal setting

Ankle-Brachial Index threshold for ischemic PAD — ABI ≤ 0.90.

ABI threshold indicating ischemic PAD

Provider Actions, Prior Authorization, and Documentation Requirements

Prior Authorization

Verify benefit and authorization requirements

Verify member benefit coverage and any prior authorization or network requirements before scheduling procedures. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws; these requirements may supersede this policy. UnitedHealthcare may use third-party tools (for example, InterQual®) or plan-specific authorizations to assist in administering benefits. This policy is informational and does not guarantee coverage or payment. Providers should confirm plan-specific eligibility, benefit limits, and prior authorization requirements through the member's benefits portal or call center.

Check federal/state/contractual plan terms that may mandate coverage or impose additional requirements
Confirm whether prior authorization is required for the requested procedure and submit requests to the correct payer portal
Use available UnitedHealthcare tools or clinical criteria (e.g., InterQual®) as applicable for authorization review

Denial Risk

Requests may be denied if criteria are not met

Background and Context

Peripheral artery disease (PAD) results from atherosclerotic narrowing of lower‑extremity arteries and commonly causes exertional leg pain (claudication) that is relieved by rest. PAD is associated with increased risk of cardiovascular events and, if progressive, can lead to Chronic Limb‑Threatening Ischemia (CLTI), which presents as rest pain, nonhealing ulcers, or gangrene and threatens limb viability. Treatment options span lifestyle modification, pharmacologic therapy, structured exercise programs, endovascular techniques (angioplasty, stents, atherectomy) and surgical bypass; the selected approach depends on symptoms, functional impairment, and lesion characteristics.

Definitions and Key Terms

Ankle-Brachial Index (ABI) definition and threshold indicating PAD.

DefinitionAnkle-Brachial Index (ABI) compares systolic blood pressure in the ankle to the arm to indicate limb perfusion

PAD thresholdAn ABI less than 0.90 indicates peripheral artery disease (PAD)

Use in criteriaABI ≤ 0.90 is required hemodynamic evidence for ischemic PAD in coverage criteria

Chronic Limb-Threatening Ischemia (CLTI) definition.

DefinitionChronic Limb‑Threatening Ischemia (CLTI) is chronic (≥2 weeks) ischemic rest pain, nonhealing wound/ulcers, or gangrene in one or both legs attributable to arterial occlusive disease

Clinical significanceCLTI is a limb‑threatening advanced form of PAD and an indication for endovascular revascularization when criteria met

Policy Revision History and Changes

2026-02-01policy_revisionLatest

Revised medically necessary coverage criteria: replaced prior imaging wording with requirement that imaging of the target vessel (duplex, CTA, MRA, or digital subtraction angiography) demonstrate anatomic location and a moderate-severe stenosis (50% or greater); added explicit retreatment criteria for in-stent restenosis requiring recurrent symptoms, impaired ADLs/work, and imaging showing ≥50% stenosis.

2026-02-01documentation_clarification

Added language clarifying medical records documentation may be required to assess whether the member meets clinical criteria, listing examples (relevant medical history, physical exam, and diagnostic test results) and requiring records be legible, maintained, and made available upon request.

Policy Summary

PayerUnitedHealthcare

PolicyLower Extremity Endovascular Procedures (for Nebraska Only)

Policy CodePolicy CS166NE.O

Change TypeRevised coverage criteriaadded in‑stent restenosis retreatment criteriaclarified imaging and documentation

Effective DateFeb 1, 2026

Next Review DateN/A

SourceLink

On This Page

Requests may be denied if the documentation or clinical criteria are not met. Common reason(s) for denial include failure to document: impaired ability to work or perform activities of daily living (ADLs); completion and failure of required conservative therapy (for claudication: at least 12 weeks of Supervised Exercise Therapy or a structured community-based exercise program plus appropriate pharmacotherapy and smoking cessation, if applicable); objective imaging evidence showing target-vessel stenosis ≥ 50% (or additional imaging when duplex does not show ≥ 50%); or recurrent symptoms for retreatment of in-stent restenosis. Denials may also occur when the diagnosis codes submitted do not match the applicable PAD/graft complication or CLTI diagnoses listed in this policy.

Documentation Required

Medical record requirements

The patient's medical record must contain legible documentation that fully supports the medical necessity of the requested service. Medical records may be requested and must be made available upon request.

Relevant medical history including symptom description, onset, impact on ADLs/work, and risk factors
Physical examination findings pertinent to lower extremity ischemia (e.g., pulses, skin changes, ulceration, gangrene)
Results of pertinent diagnostic tests or procedures (e.g., ABI, duplex ultrasound, CTA, MRA, digital subtraction angiography) with documentation of anatomic location and degree of stenosis
Documentation of prior conservative therapies: supervised exercise therapy or structured community-based program details (duration/frequency), pharmacologic therapies, and smoking cessation counseling when applicable
If proposing retreatment for in-stent restenosis — documentation of recurrent symptoms and imaging of the previously treated vessel demonstrating ≥ 50% stenosis (or alternative imaging if duplex is non-diagnostic)

Documentation Required

Required clinical detail to justify revascularization modality

To justify selection of an endovascular revascularization modality, provide clinical and anatomic details that support the chosen treatment over alternatives. The record should demonstrate the indication for revascularization and why endovascular approach is appropriate for the patient's presentation.

Clinical indication: Claudication with lifestyle-limiting symptoms despite guideline-directed medical therapy and structured/supervised exercise, or Chronic Limb-Threatening Ischemia (CLTI) with appropriate diagnosis code
Imaging/lesion characteristics: anatomic location, lesion length, degree of stenosis (moderate–severe, ≥ 50%), vessel size, presence and extent of calcification, occlusion versus stenosis, and prior stent or graft status
Treatment history: prior conservative therapies and response, prior endovascular or surgical procedures on the target vessel, and rationale for retreatment when applicable
Risk/benefit rationale: patient comorbidities, surgical candidacy, and why endovascular approach is preferred or necessary given anatomy and clinical status

Documentation Required

Medical records requirements

Ensure all required medical-record elements are present and legible before submitting an authorization request. Inadequate or missing records may delay review or result in denial. Documentation must be retained in the member's chart and made available upon request for claim or utilization review.

Maintain complete records of history, physical exam, test results, imaging reports with images when requested, and documentation of conservative management
Include dates, providers, locations, and frequency/duration details for supervised exercise or structured programs (minimum: 12 weeks when applicable)
Provide full imaging reports and, when available, vascular lab measurements (e.g., ABI) and image access for reviewer assessment

Supervised Exercise Therapy / Structured Community-Based Exercise Program — session frequency, duration, and program requirements.

Program frequencySupervised Exercise Therapy: at least 3 sessions per week

Session durationEach supervised session: 30–45 minutes of active training within a 60‑minute visit

Minimum program lengthProgram duration: minimum of 12 weeks

Program requirementsSupervised program is facility‑based and directly supervised by qualified healthcare professionals; structured community programs are prescribed, self‑directed with counseling, and may include periodic supervised sessions